CliffBio
small molecule

ERYMAX

ERYTHROMYCIN

Loss of exclusivity—loss of exclusivity
CompanyMerz Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameERYMAX
Active ingredientERYTHROMYCIN
Strength2%
Dosage formSOLUTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalJuly 1985
Marketing statusDISCN

More from Merz Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ERYMAX patent cliff — loss of exclusivity — | CliffBio